Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC
This story is reported by OncLive. Read what other outlets are saying below, then open the original report for full details.
This story is reported by OncLive. Read what other outlets are saying below, then open the original report for full details.